The low frequency of anti-TNF utilization, and, thereby, greater use of systemic steroids, may be partly attributable to higher rates of anti-TNF contraindications (decompensated congestive heart failure (CHF), malignancies) in older patients compared to their younger counterparts [18, 19]. Here, TNF is linked to congestive heart failure.